Taken together, 1α,25(OH)2D3 suppression of ANLN and ECT2, which modulate RhoA signaling, may be essential for maintaining a non-malignant prostate phenotype, which implies a novel mechanism for chemoprevention therapeutic targeting, especially for PCa in AA men. The gene discussed is ANLN; the disease is posterior cortical atrophy.